View Post

Knight Therapeutics Announces Health Canada Approval for NERLYNX® (Neratinib) to Treat HER2-Positive Metastatic Breast Cancer

In Clinical Studies News by Barbara Jacoby

Source: Knight Therapeutics From: finance.yahoo.com Knight Therapeutics Inc. (TSX: GUD), (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has approved NERLYNX® (neratinib) in combination with capecitabine for the treatment of adult patients with metastatic HER2-overexpressed/amplified breast cancer, who have received two or more prior anti-HER2-based regimens in the metastatic setting. The approval was based on results …

View Post

Knight Therapeutics Announces Health Canada Has Approved NERLYNX ® for Early-Stage Breast Cancer

In In The News by Barbara Jacoby

From: globenewswire.com Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that Health Canada has approved NERLYNX® (neratinib) for the extended adjuvant treatment of women with early-stage hormone receptor positive, HER2-overexpressed/amplified breast cancer within one year after completion of trastuzumab-based adjuvant therapy1. Knight has the exclusive right to commercialize NERLYNX® in Canada under a license agreement …

View Post

The cost of medication: Prices that are too low could reduce access

In In The News by Barbara Jacoby

SOURCE: Montreal Economic Institute From: Canada NewsWire If Health Canada achieves its goal of lowering the maximum prices for drugs, the health of Canadians could suffer, shows a Viewpoint published today by the MEI. Indeed, in countries that have implemented similar price control policies, new drugs have become less accessible to the population. “In wanting to reduce the prices of …